Octagam 10% Gains Orphan Drug Status for Rare Muscle, Skin Disorder
Octapharma announced that Octagam 10% (immune globulin intravenous [human]) Liquid has been granted Orphan Drug Designation to treat dermatomyositis, a rare disorder involving chronic inflammation and degenerative changes of the muscles and skin.
Dermatomyositis primarily presents as a skin rash immediately before or along with progressive muscle weakness. Currently, there is no cure for dermatomyositis and its cause is unknown.
Octagam 10% is currently approved to treat chronic immune thrombocytopenic purpura (ITP) in adult patients. It is supplied as 2g, 5g, 10g, or 20g single-use bottles.
For more information call (866) 766-4860 or visit Octapharma.com.